Analysguiden raises its target price for ExpreS2ion to 24 SEK per share
Hørsholm, Denmark, September 3, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case is raised to 24 SEK per share after the completion of the proposed rights issue in October 2020 at 12 SEK per share.
The raised sum-of-the-parts valuation is primarily based on the progress in the PREVENT-nCoV Covid-19 vaccine program, with phase III clinical trials expected to start in H1 2021, and ExpreS2ion’s recently announced decision to inlicense the AV001 breast cancer vaccine candicate from its joint venture AdaptVac.
The full English version of the company-sponsored equity research report is attached to this press release, while the Swedish version is available on Analysguiden’s website: https://www.aktiespararna.se/analysguiden/nyheter/analys-expres2ion-stor-uppsida-med-minskad-risk
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.
ExpreS2ion’s rights issue oversubscribed
THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIB...
I-Tech AB (publ) (ticker: ITECH) publicerar härmed sin delårsrapport för tredje kvartalet 2020
Nettoomsättningen för perioden uppgick till 11 956 (12 238) TSEK vilket motsvarar en omsätt- ningsminskning med -2 %. Rörelseresultatet uppgick till -723 (-763) TSEK. Nettoomsättningen för årets första nio månader uppgick till 41 631 (30 990) TSEK vilket mot- svarar en omsättningsökning med...
I-Tech AB (publ) (ticker: ITECH) publish the interim report for the third quarter 2020
Net turnover for the period amounted to kSEK 11 956 (12 238), corresponding to a decreasein turnover of -2%. Operating profit/loss amounted to kSEK -723 (-763). Net sales for the first nine months of the year amounted to kSEK 41 631 (30 990), corresponding to an increase in sales of 3...
Biovica's DiviTum®TKa in four posters at SABCS
The abstracts are based on international studies including the comprehensive US SWOG study, the European prospective PYTHIA study, the PROMISE study at the Mayo Clinic and a dosing study of palbociclib at Washington University. In all studies, DiviTum®TKa has been used to monitor the treatment effec...